0
0
Washington State University, August 2024 – Cannabigerol (CBG), a lesser-known cannabinoid gaining traction in the wellness community, has demonstrated potential in reducing anxiety and stress in a pioneering human clinical trial. Published in Scientific Reports, the study reveals that CBG, derived from hemp, effectively alleviated anxiety without the intoxication commonly associated with whole plant cannabis. It also suggested possible memory-enhancing benefits.
The research, spearheaded by Carrie Cuttler, an associate professor of psychology at Washington State University, marks the first human clinical trial to investigate the acute effects of CBG on anxiety, stress, and mood. Conducted in collaboration with the University of California, Los Angeles, the study involved 34 healthy cannabis users who participated in a double-blind, placebo-controlled trial.
Participants ingested either 20 mg of hemp-derived CBG or a placebo tincture in separate sessions and rated their anxiety, stress, and mood at various intervals. The results were striking: 20 mg of CBG significantly reduced anxiety levels at 20, 45, and 60 minutes post-ingestion compared to the placebo. Stress ratings also showed a notable decrease at the first time point.
Survey data from a previous study by Cuttler indicated that 51% of CBG users sought it for anxiety relief, with 78% preferring it over traditional anxiety medications. This new trial supports these claims, providing scientific validation for the cannabinoid’s efficacy.
“The rising popularity of CBG has led to numerous claims about its benefits,” said Cuttler. “Our study provides much-needed evidence to support some of these claims, helping to clarify CBG’s role in anxiety and stress management.”
In addition to its effects on anxiety and stress, the study uncovered an unexpected benefit: CBG’s impact on memory. Participants demonstrated improved recall of word lists after consuming CBG, a finding that contrasts with THC’s known memory-impairing effects. The enhancement in memory recall was statistically significant, a surprising outcome that underscores CBG’s unique properties.
Furthermore, CBG did not produce the cognitive or motor impairments typically associated with THC. Participants reported low levels of intoxication and minimal side effects such as dry mouth, sleepiness, and increased appetite. However, unlike some self-reported surveys suggesting antidepressant effects of CBG, the current study did not find significant mood enhancement.
Despite these promising results, Cuttler emphasizes caution. The study’s limitations include the use of experienced cannabis users, a relatively small dose of CBG, and the remote nature of the study conducted via Zoom. These factors, along with the absence of physiological measurements, suggest that further research is necessary.
“We must avoid overhyping CBG as a miracle drug,” cautioned Cuttler. “While the results are encouraging, replication and additional studies are essential to fully understand CBG’s benefits and safety.”
Looking ahead, Cuttler and her team plan to conduct a new clinical trial incorporating physiological measures such as heart rate, blood pressure, and cortisol levels. They also aim to expand the research to include non-cannabis users and explore CBG’s potential benefits for menopause symptoms in women.
As CBG continues to make waves in the scientific and wellness communities, ongoing research will be crucial in validating its therapeutic potential and ensuring its safe use.
